Resistance of HIV-1 to antiretroviral agents in blood and seminal plasma: Implications for transmission

AIDS

Volumn 12, Issue 15, 1998, Pages

  Eron, Joseph J ^a   Vernazza, Pietro L ^b   Johnston, David M ^b   Seillier Moiseiwitsch, Françoise ^b   Alcorn, Timothy M ^b   Fiscus, Susan A ^b   Cohen, Myron S ^b  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

AIDS; Antiretroviral therapy; HIV; Resistance; Transmission and seminal plasma

Indexed keywords

ANTIRETROVIRUS AGENT; LAMIVUDINE; NEVIRAPINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; BLOOD ANALYSIS; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESISTANCE; GENOTYPE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LONGITUDINAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; RNA SEQUENCE; SEMEN ANALYSIS; SEMINAL PLASMA; SEXUAL TRANSMISSION; VIRUS MUTANT; VIRUS TRANSMISSION;

EID: 0032558795     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199815000-00003     Document Type: Article

References (58)

1. Gulick R, Mellors J, Havlir D, et al.: Simultaneous vs. sequential initiation of therapy with indinavir, zidovudine, and lamivudine for HIV-1 infection: 100 week follow-up. JAMA 1998, 280:35-41.
2. Hammer SM, Squires K, Hughes M, et al.: A randomized, placebo-controlled trial of indinavir in combination with two nucleoside analogs in human immunodeficiency virus infected persons with CD4 cell counts less than or equal to 200 per cubic millimeter. N Engl J Med 1997, 337:725-733.
3. Busch M, Operskalski E, Mosley J, et al.: Factors influencing human immunodeficiency virus type 1 transmission by blood transfusion. J Infect Dis 1996, 174:26-33.
4. Fang G, Burger H, Grimson R, et al.: Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission. Proc Natl Acad Sci USA 1995, 92:12100-12104.
5. Sperling RS, Shapiro DE, Coombs RW, et al.: Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1996, 335:1621-1629.
6. Royce R, Sena A, Cates Jr. W, Cohen M: Current concepts: sexual transmission of HIV. N Engl J Med 1997, 336:1072-1079.
7. Vernazza PL, Eron JJ, Cohen MS, et al.: Detection and biologic characterization of infectious HIV-1 in semen of seropositive men. AIDS 1994, 8:1325-1329.
8. Vernazza PL, Gilliam BL, Dyer J, et al.: Quantification of HIV in semen: correlation with antiviral treatment and immune status. AIDS 1997, 11:987-993.
9. Coombs R, Speck C, Hughes J, et al.: Association between culturable HIV-1 in semen and HIV-1 RNA levles in semen and blood: evidence for compartmentalization of HIV-1 between semen and blood. J Infect Dis 1998, 177:320-330.
10. Dyer J, Gilliam B, Eron J, et al.: Quantitation of HIV-1 RNA in cell-free seminal plasma by NASBA amplification and Amplicor reverse transcription-PCR: a comparative study. J Virol Methods 1996, 60:161-170.
11. Cohen MS, Hoffman IF, Royce RA, et al.: Reduction of concentration of HIV-1 in semen after treatment of urethritis: implications for prevention of sexual transmission of HIV-1. AIDSCAP Malawi Research Group. Lancet 1997, 349:1868-1873.
12. Gilliam BL, Dyer JR, Fiscus SA, et al.: Effects of reverse transcriptase inhibitor therapy on the HIV-1 viral burden in semen. J Acquir Immune Defic Syndr Human Retrovir 1997, 15:54-60.
13. Gupta P, Mellors J, Kingsley L, et al.: High viral load in semen of human immunodeficiency virus type 1-infected men at all stages of disease and its reduction by therapy with protease and nonnucleoside reverse transcriptase inhibitors. J Virol 1997, 71:6271-6275.
14. Vernazza PL, Gilliam BL, Flepp M, et al.: Effect of antiviral treatment on the shedding of HIV-1 in semen. AIDS 1997, 11:1249-1254.
15. Deeks S, Loftus R, Cohen P, Chin S, Grant R: Incidence and predictors of virologic failure to indinavir (IDV) or/and ritonavir (RTV) in an urban health clinic. In 37th Interscience Conference on Antimicrobial Agents and Chemotherapy. Toronto; 1997 [LB 2].
16. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995, 374:569-571.
17. Richman D: Resistance of clinical isolates of human immunodeficiency virus to antiretroviral agents. Antimicrob Agents Chemother 1993, 37:1207-1213.
18. van Gemen B, van BR, Nabbe A, et al.: A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J Virol Methods 1994, 49:157-167.
19. Schinazi R, Larder B, Mellors J: Mutations in retroviral genes associated with drug resistance. Int Antiviral News 1997, 5:129-142.
20. Higgins D, Bleasby A, Fuchs R: Clustal V: improved software for multiple sequence alignment. CABIOS 1991, 8:189-191.
21. Learn Jr. G, Korber BT, Foley B, et al.: Maintaining the integrity of human immunodeficiency virus sequence databases. J Virol 1996, 70:5720-5730.
22. Felsenstein J: Phylogeny Inference Package. Seattle: University of Washington; 1995.
23. Felsenstein J: Evolutionary trees from DNA sequences: a maximum likelihood approach. J Mol Evol 1981, 17:368-376.
24. Saitou N, Nei M: The neighbor-joining method: a new method for reconstructing phylogenetic trees. Mol Biol Evol 1987, 4:406-425.
25. Kimura M: A simple method for estimating evolutionary rates of base substitutions through comparative studies of nucleotide sequences. J Mol Evol 1980, 16:111-120.
26. Kishino H, Hasegawa M: Evaluation of the maximum likelihood estimate of the evolutionary tree topologies from DNA sequence data, and the branching order in hominoidea. J Mol Evol 1989, 29:170-179.
27. Jukes T, Cantor C: Evolution of protein molecules. In Mammalian Protein Metabolism. New York: Academic Press; 1969:21-132.
28. Felsenstein J: Confidence limits on phylogenetics: an approach using the bootstrap. Evolution 1985, 39:783-791.
29. Zhang D, Caliendo AM, Eron JJ, et al.: Resistance to 2′,3′-dideoxycytidine conferred by a mutation in codon 65 of the human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 1994, 38:282-287.
30. Boucher CA, OSullivan E, Mulder JW, et al.: Ordered appearance of zidovudine resistance mutations during treatment of 18 human immunodeficiency virus-positive subjects. J infect Dis 1992, 165:105-110.
31. Larder BA, Kemp SD: Multiple mutations in the HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989, 246:1155-1158.
32. Harrigan PR, Kinghorn I, Bloor S, et al.: Significance of amino acid variation at human immunodeficiency virus type 1 reverse transcriptase residue 210 for zidovudine susceptibility. J Virol 1996, 70:5930-5934.
33. Hooker DJ, Tachedjian G, Solomon AE, et al.: An in vivo mutation from leucine to tryptophan at position 210 in human immunodeficiency virus type 1 reverse transcriptase contributes to high-level resistance to 3′-azido-3′-deoxythymidine. J. Virology 1996, 70:8010-8018.
34. Kellam P, Boucher CA, Larder BA: Fifth mutation in human immunodeficiency virus type 1 reverse transcriptase contributes to the development of high-level resistance to zidovudine. Proc Natl Acad Sci USA 1992, 89:1934-1938.
35. Fitzgibbon JE, Howell RM, Haberzettl CA, et al.: Human immunodeficiency virus type 1 pol gene mutations which cause decreased susceptibility to 2′,3′-dideoxycytidine. Antimicrob Agents Chemother 1992, 36:153-157.
36. Gao Q, Gu Z, Parniak MA, et al.: The same mutation that encodes low-level human immunodeficiency virus type 1 resistance to 2′,3′-dideoxyinosine and 2′,3′-dideoxycytidine confers high-level resistance to the (-) enantiomer of 2′,3′-dideoxy-3′-thiacytidine. Antimicrob Agents Chemother 1993, 37:1390-1392.
37. Schinazi RF, Lloyd RMJ, Nguyen MH, et al.: Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides. Antimicrob Agents Chemother 1993, 37:875-881.
38. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad Sci USA 1993, 90:5653-5656.
39. Richman DD, Havlir D, Corbeil J, et al.: Nevirapine resistance mutations of human immunodeficiency virus type 1 selected during therapy. J Virol 1994, 68:1660-1666.
40. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nature Med 1996, 2:760-766.
41. Condra JH, Holder DJ, Schleif WA, et al.: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J Virol 1996, 70:8270-8276.
42. Patick A, Mo H, Markowitz M, et al.: Antiviral and resistance studies of AG1343, an orally bioavailable inhibotor of human immunodeficiency virus protease. Antimicrob Agents Chemother 1996, 40:292-297.
43. Patick A, Duran M, Cao Y, et al.: Genotypic and phenotypic characterization of HIV-1 variants isolated from in vitro selection studies and from patients treated with the protease inhibitor, nelfinavir. In Fifth Workshop on HIV Drug Resistance. Whistler; 1996 [Abstract 29].
44. Kozal MJ, Shah N, Shen N, et al.: Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nature Med 1996, 2:753-759.
45. Lech WJ, Wang G, Yang YL, et al.: In vivo sequence diversity of the protease of human immunodeficiency virus type 1: presence of protease inhibitor-resistant variants in untreated subjects. J Virol 1996, 70:2038-2043.
46. de Jong MD, Veenstra J, Stilianakis NI, et al.: Host-parasite dynamics and outgrowth of virus containing a single K70R amino acid change in reverse transcriptase are responsible for the loss of human immunodeficiency virus type 1 RNA load suppression by zidovudine. Proc Natl Acad Sci USA 1996, 93:5501-5506.
47. + T-cell counts in HIV-infected patients. Ann Intern Med 1996, 124:1039-1050.
48. Gunthard H, Wong J, Ignacio C, Havlir D, Richman D: Comparative performance of high-density oligonucleotide sequencing and dideoxynucleotide sequencing of HIV Type 1 pol from clinical samples. AIDS Res Human Retrovir 1998, 14:869-876.
49. Zhu T, Wang N, Carr A, et al.: Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996, 70:3098-3107.
50. Byrn R, Zhang D, Eyre R, McGowan K, AA K. HIV-1 in semen: an isolated virus reservoir. Lancet 1997, 350:1141.
51. Delwart EL, Mullins JI, Gupta P, et al.: Human immunodeficiency virus type 1 populations in blood and semen. J Virol 1998, 72:617-623.
52. Henry K, Chinnock BJ, Quinn RP, et al.: Concurrent zidovudine levels in semen and serum determined by radioimmunoassay in patients with AIDS or AIDS-related complex. JAMA 1988, 259:3023-3026.
53. Rowe T, Beards G, Sontag G, et al.: A longitudinal study of plasma and seminal fluid HIV load on patients treated with indinavir. In International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication. St Petersburg FL; 1997 [Abstract 73].
54. Hecht F, Grant R, Petropoulos C, et al.: Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998, 339:307-311.
55. Imrie A, Beveridge A, Genn W, Vizzard J, Cooper DA: Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis 1997, 175:1502-1506.
56. Erice A, Mayers DL, Strike DC, et al.: Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med 1993, 328:1163-1165.
57. Ragni M, Faruki H, Kingsley L: Heterosexual HIV-1 transmission and viral load in hemophilic patients. J Acquir Immune Defic Syndr & Human Retrovir 1998, 17:42-45.
58. Lee TH, Sakahara N, Fiebig E, et al.: Correlation of HIV-1 RNA levels in plasma and heterosexual transmission of HIV-1 from infected transfusion recipients. J Acquir Immune Defic Syndr & Human Retrovir 1996, 12:427-428.